Abstract OBJECTIVE: To study the level of intelligence in children with Duchenne muscular dystrophy (DMD), and the relationship between the level of intelligence and gene mutations. METHODS: One hundred and two children with DMD between January 2009 and March 2011 were enrolled. DMD gene detection was performed through the multiplex ligation-dependent probe amplification (MLPA) in 84 cases. The level and the structure of intelligence were evaluated by Chinese Wechsler Intelligence Scale for Children (C-WISC) in 50 children with DMD (≥6 years old; DMD group) and in 50 age-and gender-matched healthy children (control group). RESULTS: The average intelligence quotient (IQ) was 84±21 in 102 children with DMD. Thirty patients (29.4%) had the full intelligence quotient (FIQ) less than 70. The FIQ, verbal intelligence quotient (VIQ), performance intelligence quotient (PIQ) and the scores of 11 sub-tests of intelligence in the DMD group were significantly lower than those in the control group (P<0.01). The IQ in patients with gene mutations at exon 56-79 was the lowest (59.3±11.9), followed by in patients with gene mutations at exon 45-55 (88.6±1.9), at exon 1-29 (97.5±9.6) and at exon 30-44 (102.8±3.8) (P<0.01). CONCLUSIONS: The FIQ, VIQ and PIQ in children with DMD are lower than those in healthy children. There is association between mental retardation and gene mutations.
WANG Li-Bo,MA Hong-Wei,WANG Lin et al. Relationship between gene mutations and intelligence in children with Duchenne muscular dystrophy[J]. 中国当代儿科杂志, 2011, 13(10): 804-807.
WANG Li-Bo,MA Hong-Wei,WANG Lin et al. Relationship between gene mutations and intelligence in children with Duchenne muscular dystrophy[J]. CJCP, 2011, 13(10): 804-807.
［1］Emery AE. Population frequencies of inherited neuromuscular disease-a world survey［J］. Neuromuscul Disord, 1991,1（1）: 19-29.
［2］D′ Angelo MG, Bresolin N. Cognitive impairment in neuromuscular disorders［J］. Muscle Nerve, 2006, 34(1): 16-33.
［3］Desguerre I, Christov C, Mayer M, Zeller R, Becane HM, Bastuji-Garin S, et al. Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up［J］. PLoS One, 2009, 4(2): e4347.
［8］Cotton SM,Vondouris NJ, Greenwood KM. Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis［J］. Dev Med Child Neurol, 2005,47(4): 257-265.
［9］Fabbro F, Marini A, Felisari G, Comi M, D′angelo MG, Turconi AC, et al. Language disturbances in a group of participants suffering from Duchenne muscular dystrophy: a pilot strdy［J］. Percept Mot Skills, 2007, 104 (2): 663-676.
［13］Romero NB, Benveniste O, Payan C, Braun S, Squiban P, Herson S,et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies［J］. Neuromuscul Disord, 2002, 125(pt1): 4-13.
［15］Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes［J］. Lancet Neurol, 2003, 2(12): 731-740.
［16］Moizard MP, Toutain A, Fournier D, Berret F, Raynaud M, Billard C, et al. Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening［J］. Eur J Hum Genet, 2000,8(7):552-556.
